Look for any podcast host, guest or anyone
Showing episodes and shows of

CancerNetwork

Shows

Oncology On The Go
Oncology On The GoTanios S. Bekaii-Saab, MD, Speaks to Expanding Horizons in CRC Treatment During an overview of the current standard of care for patients with colorectal cancer (CRC), Tanios S. Bekaii-Saab, MD noted that as molecular testing becomes more important, researchers are looking into how to best personalize therapy for optimal outcomes. He spoke with CancerNetwork® as part of an Around the Practice® program focused on testing and treatment options for patients with metastatic CRC.  When discussing the future direction of CRC care strategies, it is possible that treatment will be tailored to the individual based on mutation status, such as BRAF V600E, said Bekaii-Saab, leader of the Gastrointestinal Can...
2023-11-2708 minOncology On The Go
Oncology On The GoMultidisciplinary Care, Approval Updates, and Future Research in NSCLCAs part of an Around the Practice program, CancerNetwork® spoke with Misako Nagasaka, MD, PhD, about her current treatment strategies for patients with lung cancer as well as relevant updates and potential advancements in the non–small cell lung cancer (NSCLC) space. Nagasaka, a thoracic oncologist and associate clinical professor at the University of California, Irvine, discussed sequencing immunotherapy and chemotherapeutic agents depending on factors including EGFR and ALK mutations as well as a patient’s PD-L1 status. She also spoke to the importance of multidisciplinary collaboration at her practice with pulmonologists and surgeons for treating patients in th...
2023-11-1310 minOncology On The Go
Oncology On The GoPsychosocial Approach to Sexual Dysfunction During and After Cancer TreatmentSexual dysfunction is a common problem for patients with and survivors of cancer that often remains undertreated. It can manifest in a variety of ways, including reduced libido, sexual pain, and vaginal dryness. Jennifer A. Vencill, PhD, LP, takes a biopsychosocial approach to sexual health, helping to address the psychological aspects of sexual dysfunction. In this episode of the ONCOLOGY On the Go Podcast, Vencill, a psychologist and sex therapist from the Mayo Clinic, spoke with CancerNetwork® about the multidisciplinary approach her team takes to address sexual dysfunction in patients, which includes a psychologist/sex therapist, medical providers, n...
2023-11-0811 minOncology On The Go
Oncology On The GoNavigating the Impact of Chemotherapy Shortages on Cancer Care and FinancesCancerNetwork® spoke with experts across multiple disciplines about the far-reaching impacts of the ongoing shortages of chemotherapy drugs including carboplatin and cisplatin, and how practices may be able to mitigate these challenges in the short and long term.  Michael Ganio, PharmD, MS, BCPS, FASHP, described the causes of carboplatin and cisplatin being in short supply across the United States and how the FDA is working with Chinese manufacturers to import these chemotherapy agents. Ganio, senior director of Pharmacy Practice and Quality at the American Society of Health-System Pharmacists, stated that communication is paramount among all members of a...
2023-09-1121 minOncology On The Go
Oncology On The GoFrontline Forum: Testing and Targeted Therapy in EGFR Exon20+ NSCLCAs part of a CancerNetwork® Frontline Forum program, Alexander I. Spira, MD, PhD, FACP; Millie Das, MD; Joshua K. Sabari, MD; and Misako Nagasaka, MD, PhD, reviewed updates in the management of EGFR exon 20 non–small cell lung cancer (NSCLC), and how these findings may apply to clinical practice.  Spira, codirector of the Virginia Cancer Specialists Research Institute and director of the Thoracic and Phase I Program, and Das, a clinical associate professor of Medicine and Oncology at Stanford Health, led one part of the discussion regarding the evolution of molecular profiling and next-generation sequencing in the NSCL...
2023-09-0454 minOncology On The Go
Oncology On The GoFrontline Forum: Real-World Practice in Newly Diagnosed Multiple MyelomaAs part of a CancerNetwork® Frontline Forum program, Joselle Cook, MBBS; Matthew James Pianko, MD; Luciano Costa, MD, PhD; and Timothy Schmidt, MD, reviewed key data updates and real-world practice findings in newly diagnosed multiple myeloma (NDMM), and how they may impact patient subgroups including those with transplant-ineligible NDMM. Cook, a hematologist specializing in the management of patients with multiple myeloma at the Mayo Clinic in Rochester, Minnesota; and Pianko, a hematologist in the Division of Hematology and Oncology at The University of Michigan-Ann Arbor, led one part of the discussion. They discussed efficacy results from studies i...
2023-08-1449 minOncology On The Go
Oncology On The GoRelapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023In a Twitter Spaces edition of the Oncology-On-The-Go podcast, Rafael Fonseca, MD and Krina Patel, MD, MSc spoke with CancerNetwork® about how key findings from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meetingmay impact the treatment paradigm.  Fonseca, director of Innovation and Transformation Relationships at the Mayo Clinic in Phoenix, Arizona and Patel, an associate professor in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, detailed results from the phase 1b RedirecTT-1 trial (NCT04586426) assessing teclistamab-cqyv (Tecvayli) plus talquetamab in...
2023-08-0732 minOncology On The Go
Oncology On The GoSarcoma Awareness Month 2023 with Brian Van Tine, MD, PhDIn a conversation with CancerNetwork® during July’s Sarcoma Awareness Month 2023, Brian Van Tine, MD, PhD, spoke about developments in the sarcoma research space and discussed where future research needs to be focused in order to push the needle forward in the treatment of this patient across numerous sarcoma subgroups. Van Tine, a professor of medicine in the Division of Oncology, Section of Medical Oncology at Washington University School of Medicine’s Siteman Cancer Center, discussed his research on nirogacestat as a treatment for desmoid tumors as part of the phase 3 DeFi trial (NCT03785964) as well as sitra...
2023-07-3113 minOncology On The Go
Oncology On The GoOncology On-The-Go Podcast: Secondary Cancer Susceptibility in Cancer SurvivorsIn a conversation with CancerNetwork® during June’s National Cancer Survivor Month, Lindsay Morton, PhD, spoke about her research on the long-term risks of developing second cancers among cancer survivors. Morton, director of the Radiation Epidemiology Branch and head of the Cancer Survivorship Research Unit at the National Cancer Institute and member of the Lymphoma Research Foundation’s Scientific Advisory Board, discussed treatment exposure, genetics, and lifestyle elements including smoking as factors that may confer a risk for secondary cancers. She also detailed findings from her studies on second cancer risk factors across several disease types and treat...
2023-06-2720 minOncology On The Go
Oncology On The GoOncology On-The-Go Podcast: ASCO 2023 RecapRitu Salani, MD, and Tanios S. Bekaii-Saab, MD, FACP, spoke with CancerNetwork® about key findings presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, and how they may affect clinical practice for gynecologic cancer and gastrointestinal cancer. Salani, the Gynecologic Oncology Fellowship Director at University of California Los Angeles (UCLA) Health and the Gynecologic Oncology editorial board member for the journal ONCOLOGY®, discussed presentations on the treatment of ovarian cancer and other gynecologic malignancies. These included data on dostarlimab-gxly (Jemperli) in advanced or recurrent endometrial cancer in the phase 3 RUBY trial (NCT03981796), mirvetuximab soravtansine-gynx (Elahere) in...
2023-06-1939 minOncology On The Go
Oncology On The GoOncology On-The-Go Podcast: Nursing-Led Palliative Care in Advanced CancerMargaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, spoke with CancerNetwork® about findings from the CONNECT study (NCT02712229), a study she authored that aimed to assess the benefit of palliative care intervention in patients with advanced cancer. Rosenzweig, the distinguished service professor of nursing and a professor of medicine at the Hillman Cancer Center Acute & Tertiary Care, University of Pittsburgh, described the potential benefits of more frequently involving oncology nurses in discussions on advanced care planning, and helping patients make decisions on what treatment options best suit them. She also addressed some of the logistical challenges, including provider shortages a...
2023-05-1510 minOncology On The Go
Oncology On The GoOncology On-The-Go Podcast: De-escalating Breast Cancer TreatmentRakhshanda Rahman, MD, FRCS, FACS, interviewed with CancerNetwork® regarding advancements in the systemic and surgical de-escalation of breast cancer treatment, which include wire-free markers that help define the extent of a tumor during surgery. Rahman, a professor of Breast Surgical Oncology at Texas Tech University Health Sciences Center and the medical director of UMC Cancer Center, discussed de-escalation techniques including cryoablation that may aid with de-escalation beyond surgery as well as challenges surrounding physicians’ understanding of how to use new technology and educating patients on the safety and benefits of treatment options.  Don’t forget...
2023-05-0818 minOncology On The Go
Oncology On The GoOncology-On-The-Go Podcast: Signaling Pathways in Glioblastoma RelapseJavier Orozco-Mera, MD, FACS, MSc, a neurosurgeon in the Department of Neurosurgery at Hospital Universitario del Valle “Evaristo García,” University of Valle, spoke with CancerNetwork® about his study titled, Signaling Pathways in the Relapse of Glioblastoma, which was published in the journal ONCOLOGY®. In his study, Orozco-Mera and his colleagues identified a several signaling pathways and molecular processes that are involved in glioblastoma relapse, including markers such as O-6-methylguanine-DNA methyltransferase, micro-RNA, EGFR, and P53. Don’t forget to subscribe to the “Oncology On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
2023-05-0121 minOncology On The Go
Oncology On The GoOncology On-The-Go Podcast: SGO 2023 RecapIn a Twitter Spaces edition of the Oncology On-The-Go podcast, Ritu Salani, MD, and Dana Chase, MD, spoke with CancerNetwork® about findings presented at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer,and how they may impact clinical practice. Salani, the Gynecologic Oncology Fellowship Director at University of California Los Angeles (UCLA) Health and the Gynecologic Oncology editorial board member for the journal ONCOLOGY®, and Chase, associate professor of UCLA Obstetrics and Gynecology in the Division of Gynecologic Oncology, reviewed data from trials including the phase 3 NRG GY018 trial (NCT03914612),the phase 3 RUBY tria...
2023-04-2440 minOncology On The Go
Oncology On The GoOncology On-The-Go Podcast: COVID-19 Vaccination and Cellular Therapy in CancerFareed Khawaja, MBBS, assistant professor in the Department of Infectious Diseases, Infection Control, and Employee Health at The University of Texas MD Anderson Cancer Center, and Marilyne Daher, MD, medical resident in the Department of Internal Medicine at Baylor College of Medicine, spoke with CancerNetwork® about their study titled COVID-19 Vaccination in Patients with Cancer and Recipients of Cellular Therapy, which was published in the journal ONCOLOGY®. In their study, Khawaja and Daher gave an overview of the current COVID-19 vaccines that are available in the United States, published data on vaccine efficacy and safety in patients wi...
2023-04-1719 minOncology On The Go
Oncology On The GoOncology On-The-Go Podcast: Multiple Myeloma Outcome Disparities, Trial AccessIn a conversation with CancerNetwork® during March’s Myeloma Awareness Month, Krina Patel, MD, MSc, spoke about disparities in outcomes and clinical trial access for patients with multiple myeloma. Patel, associate professor in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discussed previous research focusing on how factors including gender, race, and ethnicity correlated with treatment outcomes with autologous hemopoietic stem cell transplantation and CAR T-cell therapy.  She also detailed ongoing efforts from organizations such as the FDA and the International Myeloma Foun...
2023-04-1221 minOncology On The Go
Oncology On The GoOncology On-The-Go Podcast: Integrative and Palliative Kidney Cancer CareAs part of Kidney Cancer Awareness Month 2023, Santosh Rao, MD, spoke with CancerNetwork® about recent developments and initiatives that have helped to advance integrative and palliative care for patients with kidney cancer, including developments that read out of the Annual Society for Integrative Oncology (SIO) International Conference and evidence supporting the use of non-clinical tools such as acupuncture, reflexology, acupressure, and massages.  Rao, medical director of integrative oncology for University Hospitals Connor Whole Health and president-elect for the SIO, outlined palliative care strategies employed at University Hospitals and described ongoing research and pain management guidelines that aim to...
2023-03-2822 minOncology On The Go
Oncology On The GoOncology On-The-Go Podcast: Time to Treatment for Breast Cancer in Rural PopulationsMinh-Tri Nguyen, MD, a hematology and oncology fellow at Cleveland Clinic Taussig Cancer Institute, spoke with CancerNetwork® about his study titled Shorter Time to Treatment Is Associated With Improved Survival in Rural Patients With Breast Cancer Despite Other Adverse Socioeconomic Factors, which was published in the journal ONCOLOGY®. In his study, Nguyen and his colleagues explored factors including time to treatment initiation as predictors of overall survival in rural and nonrural patients with breast cancer. Overall, their research suggested that improving time to treatment initiation can mitigate socioeconomic disparities observed in rural cancer care.  Don...
2023-02-2713 minOncology On The Go
Oncology On The GoOncology On-the-Go Podcast: Sacituzumab Govitecan for HR+/HER2– Advanced Breast CancerIn a Twitter Spaces edition of the Oncology On-the-Go podcast, Kevin Kalinsky, MD, MS, and Jane Meisel, MD, of Emory Winship Cancer Institute, spoke with CancerNetwork® about how the FDA approval of sacituzumab govitecan-hziy (Trodlevy) for advanced or metastatic hormone receptor–positive, HER2-negative breast cancer will impact the treatment paradigm. Kalinsky, an associate professor in the Department of Hematology and Medical Oncology and director of Breast Medical Oncology, and Meisel, an associate professor in the Department of Hematology and Medical Oncology and in the Department of Gynecology and Obstetrics, discussed data from the phase 3 TROPiCS-02 trial (NCT...
2023-02-2028 minOncology On The Go
Oncology On The GoOncology Peer Review On-The-Go Podcast: Cervical Cancer Screenings/Survival in Those 65+ YearsJulianne Cooley, MS, a computational and data science research specialist at the California Cancer Reporting and Epidemiologic Surveillance in the University of California Davis Comprehensive Cancer Center, spoke with CancerNetwork® about her research on cervical cancer screening and survival rate patterns among patients 65 years and older.  In her study, Cooley explored how survival rates among older patients with late-stage cervical cancer diagnoses were lower compared with those of younger patients, and how the current screening paradigm may be impacting this older population.  Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple...
2023-02-0210 minOncology On The Go
Oncology On The GoOncology Peer Review On-The-Go: Integrative Oncology in Young Population with Breast CancerYancey Warren, Jr, MD, MAT, a breast surgery oncology fellow at Brown University, and Lejla Hadzikadic-Gusic, MD, MSc, associate professor of surgery, Division of Surgical Oncology at Atrium Health Levine Cancer Institute, spoke with CancerNetwork® about their study titled Integrative Oncology in Young Women with Breast Cancer, which was published in the journal ONCOLOGY®. In their study, the authors explored the potential benefit of integrative oncology strategies to better establish referral practices for Levine Cancer Institute and define optimal timing for treatment in young patients with breast cancer.  Don’t forget to subscribe to the “Oncology Peer Review On-The...
2023-01-1616 minOncology On The Go
Oncology On The GoOncology Peer Review On-The-Go: Experts Share Multidisciplinary Takeaways From 2022 SABCSDuring the 2022 San Antonio Breast Cancer Symposium (SABCS), CancerNetwork® spoke with several multidisciplinary oncology experts from the Mayo Clinic in Rochester, Minnesota about their respective key takeaways from the presentations on developments in the breast cancer space, including surgery, radiotherapy, and biomarker research.  Judy C. Boughey, a surgical oncologist of the Division of Breast and Melanoma Surgical Oncology and the Department of Surgery, discussed her research on the impact of breast conservation therapy on local recurrence rates in multiple ipsilateral breast cancer in the phase 2 ACOSOG Z11102 (Alliance) trial (NCT01556243). Robert Mutter, MD, an associate professor of the De...
2022-12-2614 minOncology On The Go
Oncology On The GoOncology Peer Review On-The-Go: Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon CancerIbrahim Halil Sahin, MD, a medical oncologist specializing in gastrointestinal oncology and an assistant professor at the University of Pittsburgh Medical Center, Hillman Cancer Center, spoke with CancerNetwork® about his manuscript titled Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US, which was recently published in the journal ONCOLOGY®. In the article, Sahin and his colleagues explored postoperative circulating tumor DNA dynamics in early-stage colon cancer and investigated escalation and de-escalation approaches using ctDNA status as a surrogate for minimal residual disease status. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on...
2022-11-1416 minOncology On The Go
Oncology On The GoOncology Peer Review On-The-Go: Cancer Pain and Opioid Use DisorderDaniel C. McFarland, DO, and Dr. Kirk Harris, MD, both of the University of Rochester, spoke with CancerNetwork® about their manuscript titled, “Cancer Pain and Opioid Use Disorder,” which was recently published in the journal ONCOLOGY®. In the review, the authors explore current approaches for screening of opioid use disorder, evaluation of psychosocial stressors, factors that qualify the disorder, and management of patients suffering with addiction. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available. 
2022-10-3123 minOncology On The Go
Oncology On The GoOncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative OncologyCoauthors Dori Beeler, PhD, of the Levine Cancer Institute; Shelley Wang, MD, MPH, of The University of Texas MD Anderson Cancer Center; and Viraj A. Master, MD, PhD, of the Winship Cancer Institute of Emory University, spoke with CancerNetwork® about their review published in the journal ONCOLOGY® titled Cancer-Related Fatigue Outcome Measures in Integrative Oncology: Evidence for Practice and Research Recommendations. In the article, the authors and their colleagues explored negative impacts, mechanisms, and measurement concerns surrounding cancer-related fatigue. They also proposed strategies for standardization and future directions in the space.   
2022-09-1920 minOncology On The Go
Oncology On The GoOncology Peer Review On-The-Go: Current Treatments in Peripheral T-cell LymphomaRobert Stuver, MD, and Zachary D. Epstein-Peterson, MD, spoke with CancerNetwork® about a review article on the treatment of peripheral T-cell lymphoma published in the journal ONCOLOGY®.
2022-08-2219 minOncology On The Go
Oncology On The GoOncology Peer Review On-The-Go: Current Treatments in Marginal Zone LymphomaJuan Pablo Alderuccio, MD, assistant professor of medicine in the Division of Hematology, Department of Medicine at the Sylvester Comprehensive Cancer Center of the University of Miami Miller School of Medicine in Florida, spoke with CancerNetwork® about his review published in the journal ONCOLOGY® titled, Current Treatments in Marginal Zone Lymphoma. In the article, Alderuccio explored current approaches to the diagnosis and treatment of marginal zone lymphoma. He also touched on his strategies for treating localized versus advanced disease and novel emerging strategies clinicians practicing in the community should be aware of.   Don’t forget to subscribe to the “...
2022-08-0918 minOncology On The Go
Oncology On The GoOncology Peer Review On-The-Go: The Prognostic Significance of Peripheral Blood Biomarkers in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab: A Clinical StudyKira MacDougall, MD, a first year fellow at the University of Oklahoma, and Muhammad Rafay Khan Niazi, MD, a third year resident of Internal Medicine at Staten Island University Hospital, spoke with CancerNetwork® about research published in the journal ONCOLOGY® titled, The Prognostic Significance of Peripheral Blood Biomarkers in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab: A Clinical Study. MacDougall and Niazi discuss the clinical utility of absolute lymphocyte count (ALC) and the ratio of absolute neutrophil count to ALC for predicting outcomes with pembrolizumab (Keytruda) in advanced non–small cell lung cancer. They also talked...
2022-07-2514 minOncology On The Go
Oncology On The GoOncology Peer Review On-The-Go: Paolo Tarantino, MD, and Sara Tolaney, MD, Review Data in the Treatment of Breast Cancer at 2022 ASCOIn the inaugural Twitter Spaces edition of the Oncology Peer Review On-The-Go podcast hosted by CancerNetwork®, Paolo Tarantino, MD, a clinical research fellow at Dana-Farber Cancer Institute, and Sara M. Tolaney, MD, MPH, chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancer at Dana-Farber as well as an associate professor of medicine at Harvard Medical School, reviewed presentations in breast cancer research from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.  During the live event, Tarantino and Tolaney discussed the phase 3 DESTINY-Breast04 trial (NCT03734029), of fam-trastuzumab-nxki (Enhertu) vs c...
2022-06-3044 minOncology On The Go
Oncology On The GoOncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIsThis week, CancerNetwork® spoke with Judd W. Moul, MD, editorial board member for the journal ONCOLOGY® and James H. Semans, MD, Distinguished Professor of Urologic Surgery at Duke University School of Medicine, leads a discussion with medical student Kostantinos E. Morris, from Duke University School of Medicine, on research recently published in the journal ONCOLOGY®titled, ‘Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs.’  The manuscript was based on the case of a patient who presented to their clinic with elevated prostate-specific antigen (PSA) levels and multiple imaging tests that appeared...
2022-05-3021 minOncology On The Go
Oncology On The GoBetween the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple MyelomaPaul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma. As part of its Between the Lines™ video series, CancerNetwork® spoke with Paul G. Richardson, MD, clinical program leader and director of Clinical Research for the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in Boston, Massachusetts, and Christina Gasparetto, MD, professor of medicine at Duke University Medical School in Durham, North Carolina, about recent updates in the use of proteasome inhibitors for patients with multiple myeloma. In the video series, Richardson and Gasparetto discussed the...
2022-05-2022 minOncology On The Go
Oncology On The GoTanios Bekaii-Saab, MD, and Colleagues Discuss GOZILA Platform for CRCThis week, CancerNetwork turns to the second part of its 3-part series focused on colorectal cancer. Tanios Bekaii-Saab, MD, a gastrointestinal cancers (GI) medical oncologist at the Mayo Clinic Cancer Center, continues the conversation with Kristen Ciombor, MD, MSCI, a GI medical oncologist and associate professor of medicine at Vanderbilt-Ingram Cancer Center, and John Strickler, MD, a GI medical oncologist, associate professor of medicine, and co-leader of the Molecular Tumor Board at Duke University School of Medicine. This episode’s discussion turns to the GOZILA platform and its international collaboration. The experts expand on this platform, what it means fo...
2022-05-1611 minOncology On The Go
Oncology On The GoTanios Bekaii-Saab, MD, and Experts Examine Therapy Resistance in CRCThis week, CancerNetwork looks at the final part of its 3-part series focused on colorectal cancer. Tanios Bekaii-Saab, MD, a gastrointestinal cancers (GI) medical oncologist at the Mayo Clinic Cancer Center, concludes his conversation with Kristen Ciombor, MD, MSCI, a GI medical oncologist and associate professor of medicine at Vanderbilt-Ingram Cancer Center, and John Strickler, MD, a GI medical oncologist, associate professor of medicine, and co-leader of the Molecular Tumor Board at Duke University School of Medicine. This conversation focuses on resistance to targeted therapies in metastatic colorectal cancer, and the importance of addressing it. The experts also discuss...
2022-05-1616 minOncology On The Go
Oncology On The GoTanios Bekaii-Saab, MD, Talks COLOMATE Platform for CRC With GI ExpertsThis week, CancerNetwork kicks off the first of a 3-part podcast series focused on colorectal cancer. Tanios Bekaii-Saab, MD, a gastrointestinal cancers (GI) medical oncologist at the Mayo Clinic Cancer Center, leads a conversation with Kristen Ciombor, MD, MSCI, a GI medical oncologist and associate professor of medicine at Vanderbilt-Ingram Cancer Center, and John Strickler, MD, a GI medical oncologist, associate professor of medicine, and co-leader of the Molecular Tumor Board at Duke University School of Medicine. This conversation focuses on the current molecular treatment landscape of advanced colorectal cancer and the need for the COLOMATE platform. Among other...
2022-05-0916 minOncology On The Go
Oncology On The GoOncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid CancerAs part of its OncView™ program, CancerNetwork hosted a discussion Lori Wirth, MD, associate professor of medicine at Harvard Medical School and medical director of the Center for Head and Neck Cancers at Massachusetts General Hospital in Boston, who shared her perspective on updates in the treatment of second-line radioiodine-refractory differentiated thyroid cancer, or DTC. In the video series, some of the content discussed included: ·      Presentation and Disease Course of Differentiated Thyroid Cancer ·      Frontline Treatment Options for RAI-refractory DTC ·      Treatment Options in RAI-refractory DTC in Second Line and Beyond ·      Facing Unmet Needs and Ongoing Trials in RR-DTC To watch more videos...
2022-05-0634 minOncology On The Go
Oncology On The GoOncView™ Podcast: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management in Metastatic RCCAs part of its OncView™ video series, CancerNetwork® spoke with David H. Aggen, MD, PhD, of the Memorial Sloan Kettering Cancer Center, Robert S. Alter, MD, of the John Theurer Cancer Center, Arnab Basu, MD, MPH, of the O’Neal Comprehensive Cancer Center, Mehmet Asim Bilen, MD, of Winship Cancer Institute, and Chung-Han Lee, MD, MPH, of Memorial Sloan Kettering Cancer Center, who shared their thoughts on recent advances in treatment options for metastatic renal cell carcinoma (RCC) and commented on emerging data in the field. To watch more videos in the CancerNetwork® OncView™ series, visit cancernetwork.com/oncview...
2022-04-2930 minOncology On The Go
Oncology On The GoBetween the Lines™ Podcast: Mobocertinib Use in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive mNSCLCOncView™ Podcast: Mobocertinib Use in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive mNSCLC   As part of its OncView™ video series, CancerNetwork® spoke with Gregory Riely, MD, PhD, vice chair of Clinical Research in the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York, and Tarek Mekhail, MD, a hematologic oncologist from Advent Health in Florida, about patients with EGFR exon 20 insertion-positive metastatic non–small cell lung cancer who recieved mobocertinib.     In the video series, Gregory Riely, MD, PhD, and Tarek Mekhail, MD, discussed the following:  Mobocertinib Use in mNSCLC: EXCLAIM Cohort Study Design ...
2022-04-2727 minOncology On The Go
Oncology On The GoCharacterization of Blood-Based Molecular Profiling in Pancreatic AdenocarcinomaThis week, CancerNetwork® spoke with Christine Chung, DO, of the Swedish Medical Center, Englewood, Colorado, about “Characterization of Blood-Based Molecular Profiling in Pancreatic Adenocarcinoma,” a retrospective review published in the journal ONCOLOGY. Chung detailed this research, which characterizes the mutational landscape of patients with metastatic pancreatic adenocarcinoma who received blood-based molecular profiling. A total of 77 consecutive patients were included in the analysis. Chung also spoke about pancreatic adenocarcinoma, the study’s main findings, and how this research can inform future treatment decision-making processes moving forward. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podc...
2022-04-2508 minOncology On The Go
Oncology On The GoPARP Inhibitors as Maintenance Therapy for Metastatic CRPCThis week, CancerNetwork® spoke with Muhammad Niazi, MD, resident in internal medicine at Staten Island University Hospital, and Alexander Bershadskiy, MD, attending physician at Staten Island University Hospital, about a meta-analysis published in ONCOLOGY titled, “Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.” The final analysis evaluated 3 randomized clinical trials. A fixed model showed a statistically significant improvement in overall survival for patients with metastatic castration-resistant prostate cancer treated with PARP inhibitors. The authors provided a detailed background on PARP inhibitors and further detailed the results of this resea...
2022-04-1113 minOncology On The Go
Oncology On The GoOncView™ Podcast: EGFR Exon 20 Insertion as Therapeutic Target in NSCLCAs part of its OncView™ video series, CancerNetwork® spoke with Zofia Piotrowska, MD, an assistant professor of medicine at Harvard Medical School and a lung cancer medical oncologist at Massachusetts General Hospital, about recent data and review updates in the treatment landscape for patients with non-small-cell lung cancer and exon 20 insertions. In the video series, Piotrowska discussed the following: ·      Overview of Advanced NSCLC with EGFR Mutations Including Exon 20 Insertions ·      Testing for the EGFR Exon 20 Insertion ·      Historical Treatment Approach for EGFR Exon 20 Insertions in NSCLC ·      Amivantamab for the Treatment of EGFR Exon 20 Insertions in NSCLC ·      Mobocertinib for the Treatment of EGFR Exon 20 Inserti...
2022-04-0821 minOncology On The Go
Oncology On The GoBetween the Lines™ Podcast: ctDNA as a Biomarker of Progression in Colorectal CancerAs part of its Between the Lines™ video series, CancerNetwork® spoke with Liliana Bustamante, MD, hematologist and medical oncologist at Florida Cancer Specialists in Fort Myers, Florida and Richard Kim, MD, service chief of Medical Gastrointestinal Oncology and senior member in the Gastrointestinal Oncology Department at the Moffitt Cancer Center in Tampa, Florida, about the prognostic potential of circulating tumor DNA (ctDNA) as a biomarker for patients with oligometastatic colorectal cancer. In the video series, Bustamante and Kim discussed the following: ·      Presentation: ctDNA Assays For Patients With CRC Undergoing Resection of Metastases ·      Key Takeaways: ctDNA Assays For Patients With CRC Un...
2022-04-0525 minOncology On The Go
Oncology On The GoOncView™ Podcast: Immunotherapy Response Monitoring in MelanomaAs part of its OncView™ video series, CancerNetwork® spoke with John Kirkwood, MD, PhD, director of the melanoma center at the University of Pittsburgh Medical Center Hillman Cancer Center, about using immunotherapy for treating melanoma and how to monitor responses in patients properly. In the video series, Kirkwood discussed the following: ·      Treatment Options for Melanoma ·      Considerations for Immunotherapy Use When Treating Melanoma ·      Monitoring Responses to Melanoma Therapy ·      Pseudoprogression in Melanoma Therapy ·      ctDNA for Melanoma Treatment Monitoring ·      Using ctDNA to Monitor Patients With Melanoma ·      Taking Drug Holidays Amidst Melanoma Therapy ·      Duration of Treatment for Melanoma To watch more videos in CancerNetwork®’s OncView™...
2022-04-0243 minOncology On The Go
Oncology On The GoOncView™ Podcast: Immunotherapy Response Monitoring in Lung CancerAs part of its OncView™ video series, CancerNetwork® spoke with Roy Herbst, MD, PhD, chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, about currently available treatment options and strategies in immunotherapy for treating non–small cell lung cancer (NSCLC). In the video series, Herbst discussed the following: ·      Treatment Options in Non–Small Cell Lung Cancer ·      Monitoring Response to Therapy in NSCLC ·      Role of ctDNA in Monitoring Treatment Response in NSCLC ·      Clinical Decision-Making in NSCLC ·      Recap: Monitoring With ctDNA for Immunotherapy Response in Lung Cancer To watch more videos in CancerNetwork®’s OncView...
2022-03-3018 minOncology On The Go
Oncology On The GoReal-World Assessment of Care and Efficiency With Subcutaneous RituximabThis week, CancerNetwork spoke with Matthew Matasar, MD, a lymphoma specialist and chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center Bergen, about research from the December issue of ONCOLOGY titled, “Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab.” The retrospective, observational analysis examined patient care delivery and practice efficiency changes using real-world data. Patients with diffuse large B-cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia who received a rituximab-containing regimen were eligible for the study. Matasar touched on subcutaneous rituximab, the role it can play in treatment, the time...
2022-03-2810 minOncology On The Go
Oncology On The GoNeoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder CancerCancerNetwork spoke with Jun Gong, MD, a practicing medical oncologist who specializes in the treatment of genitourinary cancers at Cedars-Sinai Medical Center, regarding a perspective piece titled, “Cisplatin Neoadjuvant Chemotherapy in an Aging Population With Muscle-Invasive Bladder Cancer.” Gong’s perspective focuses on an article published in the January issue of ONCOLOGY titled, “Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based Study, 2006-2017.” In this conversation, Gong overviewed the research and touched on some of the clinically relevant findings. He then detailed his perspective and expanded on cisplatin-based chemotherapy, how age fits into the treatm...
2022-03-1413 minOncology On The Go
Oncology On The GoOfer Sharon, MD, Discusses OncoHost and PROPHETIC TrialCancerNetwork® recently spoke with Ofer Sharon, MD, CEO of OncoHost, about interim results from the prospective PROPHETIC trial to predict how patients with non–small cell lung cancer respond to immunotherapy. Sharon first described OncoHost and the mission of this clinical stage precision oncology company. Then, he touched on the key details of this research, with a focus on the PROphet diagnostic platform at the center of this ongoing multicenter clinical trial, as well as what comes next for this research and OncoHost. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify o...
2022-02-2814 minOncology On The Go
Oncology On The GoMetastatic Basal Cell Carcinoma Arising From a Primary Cutaneous CarcinosarcomaCancerNetwork® spoke with Emily Smith, MD, of the Ellis Fishchel Cancer Center, University of Missouri, about a patient case published in the December issue of the journal ONCOLOGY titled, “Metastatic Basal Cell Carcinoma Arising From a Primary Cutaneous Carcinosarcoma.” Smith and colleagues detailed a case regarding a 56-year-old man who the team of care providers diagnosed with metastatic basal cell carcinoma arising from a carcinosarcoma. In the conversation, Smith talked about what makes this patient case unique, the timeline of this specific patient’s disease and treatment, the rarity of basal cell carcinoma arising from a carcinosarcoma, and plenty more.
2022-02-1412 minOncology On The Go
Oncology On The GoMatthew Allaway, DO, on Transperineal Biopsy Approach for Prostate CancerCancerNetwork spoke with Matthew Allaway, DO, founder and CEO of Perineologic, about a new prostate cancer biopsy technique that uses the transperineal approach to detect cancer in harder to reach areas of the prostate. Allaway touched on the American Cancer Society’s annual report that shows the rate of advanced-stage prostate cancer cases are increasing in recent years. He also detailed a companion study to that report, and walked through the specific details and benefits of this biopsy technique. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere...
2022-01-3118 minOncology On The Go
Oncology On The GoAmy Comander, MD, on SABCS and Key Breast Cancer Data from 2021This week, CancerNetwork closed the book on the year that was 2021. CancerNetwork spoke with Amy Comander, MD, co-medical director and director of breast oncology and cancer survivorship at Mass General Cancer Center, about some of the key developments and data to emerge from 2021 for patients with breast cancer, with a specific focus on the 2021 San Antonio Breast Cancer Symposium (SABCS). Not only did Comander detail important information from 2021 in the field of breast cancer, but she also touched on how the field is continuously evolving and shared her thoughts on what’s in store for patients in 2022. Don’t fo...
2022-01-1713 minOncology On The Go
Oncology On The GoBetween the Lines™ Podcast: Incorporating Real-World Evidence into Clinical Decisions in NSCLCAs part of its Between the Lines™ video series, CancerNetwork® spoke with Lyudmila Bazhenova, MD, a professor of medicine at the University of California San Diego Health, and Federico Albrecht, MD, an oncologist/hematologist at Miami Cancer Institute, Baptist Health South Florida, about when and how to use real-world evidence when making treatment decisions for patients with EGFR-mutated non–small cell lung cancer (NSCLC). In the video series, Bazhenova and Albrecht discussed the following: ·      Presentation: Benefits and Limitations of RWE: Lessons From EGFR Mutation-Positive NSCLC ·      EGFR-Mutant NSCLC: Addressing Gaps When Collecting Data ·      Experts in Treating EGFR-Positive NSCLC Compare Randomized Trials...
2022-01-1441 minOncology On The Go
Oncology On The GoImproving Experience of LGBTQ+ Patients in Cancer CareThis week, CancerNetwork spoke with Don Dizon, MD, about certain unique challenges LGBTQ+ patients face when navigating through their cancer journey, and how providers can improve these experiences. The director of women’s cancers at the Lifespan Cancer Institute, director of medical oncology at Rhode Island Hospital, and professor of medicine at the Warren Alpert Medical School of Brown University in Providence, touched on overcoming barriers in clinical cancer research, creating a gender-affirming environment for patients, and other important topics for treating LGBTQ+ patients with cancer. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Po...
2022-01-0326 minOncology On The Go
Oncology On The GoFuture Directions in Small Cell Lung Cancer TreatmentThe final episode of CancerNetwork’s 4-part series on small cell lung cancer (SCLC) welcomes back Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center. In this conversation, Iams looks to the future of SCLC treatments, touching on topics including extending response durations for patients, emerging therapies for extensive stage SCLC, exciting research on the horizon, and more. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available. Check out the previous podcast episodes in this series: ·      Episode 1: First-Line Therapeutic Options in Small Cell Lun...
2021-12-2207 minOncology On The Go
Oncology On The GoPractical Considerations for Small Cell Lung Cancer Therapeutic OptionsIn the third part of a 4-part series on small cell lung cancer (SCLC), CancerNetwork spoke with Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center. The conversation focused on the toxicities of treatment options, quality of life for patients, and how Iams suggests managing and mitigating those events for individuals with SCLC. Some of the agents and regimens discussed include lurbinectedin and trilaciclib, as well as chemotherapy and immunotherapy. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available. Check out the pr...
2021-12-1613 minOncology On The Go
Oncology On The GoIncreasing Testing Access and Guiding Treatment Options with TrialJectoryThis week’s conversation focuses on TrialJectory, a digital health company that utilizes artificial intelligence to inform patients with cancer on their treatment journey. CancerNetwork spoke with Tzvia Bader, CEO and co-founder of TrialJectory, and Karine Perreault, who recently was diagnosed with breast cancer and is on the TrialJectory platform. The conversation touches on the perceived disconnect between the pharmaceutical industry and patients, the need to remove barriers to access testing, and the action items they thinks need to be prioritized to improve access for women with cancer. Don’t forget to subscribe to the "Oncology Peer Revi...
2021-12-0620 minOncology On The Go
Oncology On The GoTreatment Options for Relapsed/Refractory Small Cell Lung CancerIn the second part of a 4-part series on small cell lung cancer, CancerNetwork continued its conversation with Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center. Iams turned the attention to different treatment options for patients with relapsed/refractory small cell lung cancer. Among others, Iams touched on lurbinectedin, topotecan, and some of the crucial clinical trials associated with treatment options for small cell lung cancer, including a phase 2 basket trial and phase 3 ATLANTIS trial examining lurbinectedin. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or an...
2021-12-0213 minOncology On The Go
Oncology On The GoValue of Geriatric Assessment in Patients With Genitourinary CarcinomaCancerNetwork looks at research from the October issue of the journal ONCOLOGY, titled “Value of Geriatric Assessment in Patients With Genitourinary Carcinoma.” Lead author, Quirin Zangl, MD, from the Department of Neuroanesthesia, at the Christian Doppler Hospital in Salzburg, Austria, spoke in detail about the manuscript. The research featured 111 patients with urogenital carcinomas with the goal of evaluating comprehensive geriatric assessment tools to better guide these individuals. Patients were divided into 2 groups, which were prostate cancer (n = 88) and distal urinary tract cancer (n = 29). Overall, the relationships between comprehensive geriatric assessment tools and complications, hospital duration, death rate, and baseline char...
2021-11-2208 minOncology On The Go
Oncology On The GoGermline Testing in Prostate Cancer: When and Who to TestThis week, CancerNetwork looks at an article from the October issue of the journal ONCOLOGY, titled “Germline Testing in Prostate Cancer: When and Who to Test.” CancerNetwork spoke with one of the authors of this article, Alexandra Sokolova, MD, an assistant professor at Oregon Health & Science University. Sokolova detailed the article, which summarizes germline testing recommendations for prostate cancer, specifically looking at the recently updated NCCN guidelines, as well as describing care models for providing counsel and testing for patients. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhe...
2021-11-0818 minOncology On The Go
Oncology On The GoFirst-Line Therapeutic Options in Small Cell Lung CancerIn this special episode of the "Oncology Peer Review On-The-Go" podcast, CancerNetwork spoke with Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center, about therapeutic advances for small cell lung cancer. Iams discussed the current first-line therapies for small cell lung cancer, the IMpower133 and CASPIAN trials, and the factors considered for treating patients in the first-line setting.  Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
2021-11-0110 minOncology On The Go
Oncology On The GoOncView™ Podcast: Connie Batlevi, MD, PhD on R/R Follicular Lymphoma Therapy UpdatesAs part of its OncView video series, CancerNetwork spoke with Connie Batlevi, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, about recent updates in therapies for relapsed or refractory follicular lymphoma. Batlevi discussed the current treatment options for this disease, as well as third-line therapies, tazemetostat, and sequencing changes. In the video series, Batlevi discussed the following: ·      Current Treatment Options and Considerations for Relapsed/Refractory Follicular Lymphoma ·      Third-Line Therapies in R/R FL ·      Use of Tazemetostat in R/R FL ·      Sequencing Changes in R/R FL Therapies To watch more videos in CancerNetwork®’s OncView™ series, vi...
2021-10-2925 minOncology On The Go
Oncology On The GoDebra Patt, MD, PhD, MBA, FASCO, on Telehealth in Cancer CareThis week, CancerNetwork spoke with Debra Patt, MD, PhD, MBA, FASCO, Executive Vice President at Texas Oncology. Patt discussed the rise of telehealth during the COVID-19 pandemic, how clinicians can use these tools to help treat patients with cancer, and the role of telemedicine moving forward. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
2021-10-2511 minOncology On The Go
Oncology On The GoBetween the Lines: PET/CT-Guided Postprostatectomy Salvage Radiotherapy for Prostate CancerAs part of CancerNetwork’s Between the Lines video series, Brian Helfand, MD, PhD, Chief of the Division of Urology and the Ronald L. Chez Family and Richard Melman Family Endowed Chair at NorthShore University HealthSystem, and Steven Finkelstein, MD, FACRO, a radiation oncologist with Florida Cancer Affiliates US Oncology Network in Panama City, Florida, examined the results and clinical implications of the phase 2/3 EMPIRE-1 trial in prostate cancer. The trial compares 18F-fluciclovine PET/CT imaging versus conventional imaging to guide postprostatectomy salvage radiotherapy. To watch more videos in CancerNetwork’s Between the Lines series, visit cancernetwork.com.
2021-10-1936 minOncology On The Go
Oncology On The GoPlasma Glutamine as a Prognostic Biomarker in Localized Prostate CancerThis episode features an examination of an article from the September issue of the journal ONCOLOGY, titled “Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification.” CancerNetwork spoke with one of the authors of this research, Jun Gong, MD, a practicing medical oncologist with an emphasis in GU cancers at Cedars-Sinai Medical Center. Gong detailed PSA’s role in prostate cancer, and other potential complementary biomarkers. He also discussed some of the significant findings from his research on plasma glutamine, which featured a cohort of over 100 patients with localized prostate cancer.
2021-10-1115 minOncology On The Go
Oncology On The GoScaleReady’s Work to Make Cell and Gene Therapy Practical and ViableThis week, CancerNetwork spoke with Josh Ludwig, Global Director of Commercial Operations at ScaleReady, about how this joint venture between industry leaders launched in January, is uniquely positioned to make cell and gene therapy practical and viable. Ludwig elaborated on how ScaleReady can support the entire industry, now and into the future, with a manufacturing platform that delivers a high throughput and efficient use of space. He also discussed G-Rex closed-system bioreactors, important processes for successful commercialization of cell and gene therapy, and what’s next for ScaleReady. Don’t forget to subscribe to the "Oncology Peer Review On-T...
2021-09-2724 minOncology On The Go
Oncology On The GoInside the Advancing Inclusive Research Site Alliance for Clinical Trial DiversityCancerNetwork spoke with Quita Highsmith, Vice President and Chief Diversity Officer for Genentech, and Monica Baskin, PhD, a professor of preventive medicine and associate director for Community Outreach and Engagement for the O’Neal Comprehensive Cancer Center in Birmingham, Alabama. The conversation focused on the Advancing Inclusive Research Site Alliance, which is a coalition of clinical research sites partnering with Genentech to advance representation of diverse patient populations in oncology clinical trials. Results from clinical trials without diverse patient cohorts are rarely generalizable to the entire population, and this initiative works to educate and inform the clinicians and researchers to...
2021-09-1318 minOncology On The Go
Oncology On The GoTwo Experts Review Important R/R DLBCL Treatment Decisions and DataFor the final installment of a 3-part relapsed/refractory DLBCL series, CancerNetwork heard from Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, and Kami Maddocks, MD, an associate professor of clinical internal medicine in the Division of Hematology at The Ohio State University Wexner Medical Center. These lymphoma experts spoke about their thoughts on data from the L-MIND trial, when to implement CAR-T cell therapies for patients, the role of Selinexor in treating patients, and a host of other important ideas. Don’t forget to subscribe to the On...
2021-08-3018 minOncology On The Go
Oncology On The GoOncView™ Podcast: Updates in Therapies of Relapsed/Refractory Follicular LymphomaAs part of its OncView™ video series, CancerNetwork® spoke with Javier Munoz, MD, MS, FACP, from the Mayo Clinic in Phoenix, Arizona, about updates in therapies of relapsed/refractory follicular lymphoma. In the video series, Javier Munoz, MD, MS, FACP, discussed the following: ·      Current Treatment Options for Relapsed/Refractory Follicular Lymphoma ·      Factors in Choosing R/R FL Treatments ·      Treatment Options for Third-Line R/R FL ·      Use of Tazemetostat for R/R FL ·      Changes in Sequencing of R/R FL Therapies To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.
2021-08-2520 minOncology On The Go
Oncology On The GoOncView™ Podcast: NCCN Guideline Updates in HR+ Breast CancerAs part of its OncView™ video series, CancerNetwork® spoke with Lee Schwartzberg, MD, FACP, of the West Cancer Center and Research Institute in Germantown, Tennessee, about updates to the National Comprehensive Cancer Network (NCCN) guidelines regarding hormone receptor (HR)–positive breast cancer. In the video series, Lee Schwartzberg, MD, FACP, discussed the following: ·      Extended Adjuvant Therapy for HR+ Breast Cancer ·      Molecular Biomarkers for HR+ Breast Cancer ·      Role of Genomic Testing in HR Positive Breast Cancer ·      Appropriateness for Genomic Testing in HR+ Breast Cancer ·      Integration of Genomic Testing into NCCN Guidelines ·      Current Recommendations for Genomic Testing in HR+ Breast Cancer ·      Treatment Limi...
2021-08-2023 minOncology On The Go
Oncology On The GoRoutine Breast Cancer Screening in Average-Risk Women Younger Than 50 YearsThis week's podcast focuses on a review article published in the June issue of the journal ONCOLOGY titled, “Routine Breast Cancer Screening in Average-Risk Women Younger Than 50 Years: Current Paradigms Based on National Guidelines.” CancerNetwork spoke with Anath Ravi, PhD, co-founder and chief science and clinical officer of MOLLI Surgical, and Randy Miles, MD, MPH, an assistant professor in the Department of Radiology and clinical service chief in the Division of Breast Imaging at Massachusetts General Hospital, about their work with breast cancer screenings for women under the age of 50. The conversation focused on the current breast cancer screening guid...
2021-08-1630 minOncology On The Go
Oncology On The GoExamining Evidence Underlying the NCCN Guidelines for Hematologic MalignanciesThis week, CancerNetwork review an article published in the July issue of the journal ONCOLOGY titled, “Level of Scientific Evidence Underlying the National Comprehensive Cancer Network Clinical Practice Guidelines for Hematologic Malignancies.” CancerNetwork spoke with Thejaswi Poonacha, MD, MBA, a staff physician and hospitalist in the department of internal medicine at the University of Minnesota Medical Center, regarding the research from him and his colleagues. The conversation focused on the scientific evidence behind the NCCN guidelines for hematologic malignancies, how each category corresponds with different levels of evidence, and the main findings from this study. Poonacha shared exactly what this...
2021-08-0215 minOncology On The Go
Oncology On The GoKami Maddocks, MD, on Rituximab Rechallenging and Second-Line Therapies for R/R DLBCLCancerNetwork spoke with Kami Maddocks MD, an associate professor of clinical internal medicine in the Division of Hematology at The Ohio State University, about CD-19 directed agents, avoiding rechallenging with rituximab, and second-line outcomes for transplant-ineligible patients with diffuse large B-cell lymphoma (DLBCL).   Visit cancernetwork.com to check out the first episode of this 3-part series here. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
2021-07-3014 minOncology On The Go
Oncology On The GoConsidering Second-Line Treatment Amidst Evolving Frontline Landscape for Clear Cell RCCThis week, CancerNetwork® examined an article from the June issue of the journal ONCOLOGY® titled “Second-Line Therapies in the Changing Landscape of First-Line Therapies for Metastatic Clear Cell Renal Cell Cancer” by speaking with one of the authors, Robert A. Figlin, MD.   Figlin, who is a professor of medicine and biomedical sciences, Steven Spielberg Family Chair in Hematology-Oncology, and deputy director of Cedars-Sinai Cancer at the Cedars-Sinai Medical Center in Los Angeles, California, spoke about the evolving treatment paradigm of metastatic clear cell renal cell carcinoma, specifically how the shifting landscape of first-line therapies has impacted second-line therapeutic strategies. He discuss...
2021-07-1915 minOncology On The Go
Oncology On The GoOncView™ Podcast: Updates in Managing Extensive-Stage Small Cell Lung CancerAs part of its OncView™ video series, CancerNetwork® spoke with Benjamin Levy, MD, of the John Hopkins Sidney Kimmel Comprehensive Cancer Center, to discuss frontline management of extensive-stage small cell lung cancer (SCLC) and the recent updates in the field.   In the video series, Levy discussed the following:   ·      Small Cell Lung Cancer: Risk and Prognosis ·      Small Cell Lung Cancer: Standard of Care ·      Extensive-Stage Small Cell Lung Cancer: Gaps in Treatment ·      Immunotherapy for First-Line Extensive-Stage SCLC ·      First-Line I-O Plus Chemotherapy for Extensive-Stage SCLC ·      Significance of the IMpower133 Trial in Extensive-Stage SCLC   To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.   Don’t...
2021-07-1635 minOncology On The Go
Oncology On The GoBPCIA, 4-Letter Suffix Rule, & the Challenges of Biosimilar PrescriptionIn this episode, CancerNetwork spoke with 2 experts on the topic of biosimilars, Howard Hochster, MD, FACP, Associate Director for Clinical Research at the Rutgers Cancer Institute of New Jersey and Distinguished Professor of Medicine at the Rutgers School of Medicine, and Michael Kane, RPh, BCOP, Executive Director of Oncology Pharmacy Services for RWJBarnabas Health and Director of Pharmacy Services and the Research Pharmacy at the Rutgers Cancer Institute of New Jersey. The episode dives into the background of biosimilars, including the Biologics Price Competition and Innovation Act (BPCIA) passed by the United States Congress in 2009 and subsequent 4-letter suffix...
2021-07-0527 minOncology On The Go
Oncology On The GoEmerging and Existing Treatment Regimens for Transplant-Ineligible DLBCLIn this episode, CancerNetwork spoke with Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, about recently approved and emerging treatment regimens for transplant-ineligible diffuse large B-cell lymphoma (DLBCL). Salles discussed some of the available treatment options including tafasitamab, CAR T-cell therapies, selinexor, and antibody drug conjugates (ADCs). He also looked ahead at some of the upcoming research on the horizon, including the B-MIND trial investigating tafasitamab or rituximab plus bendamustine.
2021-06-3026 minOncology On The Go
Oncology On The GoOncView Podcast: Front-Line Management of Extensive-Stage SCLCAs part of the OncView video series, CancerNetwork spoke with Mark Socinski, MD, of the AdventHealth Cancer Institute in Orlando, Florida about updates in the management of extensive-stage small cell lung cancer (ES-SCLC). Socinski touched on a number of important aspects of treating this disease, including the existing standards of care, treatment challenges, immunotherapy, IMpower 133 trial, and more. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast wherever you get your podcasts.
2021-06-2827 minOncology On The Go
Oncology On The GoMolecular Profiling Practices in Pancreatic AdenocarcinomaThis week, "Oncology Peer Review On-The-Go" discussed an article from the May issue of the journal ONCOLOGY titled “Molecular Profiling Practices in Pancreatic Adenocarcinoma: Academic vs Community Physicians.” CancerNetwork spoke with Christine Chung, DO, from the HCA Swedish Medical Center in Englewood, Colorado, about the molecular profiling patterns she and her colleagues observed in this retrospective review. The authors found that both academic and community physicians ordered profiling about 50% of the time, which was contrary to previous reports that suggest academic centers perform molecular profiling more often. The perspective for this article comes from Roman Groisberg, MD, a medical onco...
2021-06-2129 minOncology On The Go
Oncology On The GoOncView™ Podcast: Management of Relapsed/Refractory Follicular LymphomaAs part of its OncView™ video series, CancerNetwork® spoke with Sameh Gaballa, MD, of the Moffit Cancer Center, about current and future treatment options, and considerations for patients with relapsed/refractory follicular lymphoma.   In the video series, Gaballa discussed the following: ·      Treatment Options in Relapsed/Refractory Follicular Lymphoma ·      Considerations for Treatment Selection in R/R FL ·      Third-Line Therapy in Follicular Lymphoma ·      Tazemetostat for Relapsed/Refractory Follicular Lymphoma ·      R/R FL: The Role of PI3K Inhibitors ·      Unmet Needs and Looking Ahead in Follicular Lymphoma   To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.
2021-06-1729 minOncology On The Go
Oncology On The GoOncView Podcast: Optimizing Treatment With Extended Adjuvant Therapy for HR+ Breast CancerAs part of its OncView video series, CancerNetwork spoke with Reshma L. Mahtani, DO, Sylvester Comprehensive Cancer Center, about the current role of genomic testing in HR-positive breast cancer and guidance on the use of genomic assays to individualize therapy in the extended adjuvant setting.   In the video series, Gadi discussed the following: ·      Extended Adjuvant Therapy for HR+ Breast Cancer ·      NCCN Updates to Genomic Testing in HR+ Breast Cancer ·      Genomic Testing for HR+ Breast Cancer: Best Practices ·      Utilization of The Breast Cancer Index for HR+ Breast Cancer ·      Optimizing Treatment Outcomes in HR+ Breast Cancer   To watch more videos in CancerNetwork’s OncView series, visit
2021-05-1916 minOncology On The Go
Oncology On The GoOncView Podcast: Genomic Testing in HR+ Breast Cancer to Guide Therapy in the Extended Adjuvant SettingAs part of its OncView video series, CancerNetwork spoke with Vijayakrishna (VK) Gadi, MD, PhD, University of Illinois College of Medicine, about the current role of genomic testing in HR-positive breast cancer and guidance on the use of genomic assays to individualize therapy in the extended adjuvant setting.   In the video series, Gadi discussed the following: ·      Adjuvant Vs Extended Adjuvant Therapy in HR+ Breast Cancer ·      Predictive and Prognostic Factors in HR+ Breast Cancer ·      Role of Genomic Testing in HR+ Breast Cancer ·      NCCN Guideline Updates for the Use of Genomic Assays in HR+ Breast Cancer ·      Identifying Patients for Extended Adjuvant Therapy With the Breast Cance...
2021-05-1826 minOncology On The Go
Oncology On The GoIntegrating PARP Inhibitors Into Advanced Prostate Cancer TherapeuticsThis episode features an article published in the Journal ONCOLOGY titled “Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics.” CancerNetwork spoke with the corresponding author, Jun Gong, a medical oncologist at Cedars-Sinai Medical Center, to discuss the 4 PARP inhibitors that have undergone significant investigation for the treatment of patients with metastatic castrate-resistant prostate cancer. While elaborating on these PARP inhibitors, Gong also discussed the importance and potential value of successfully integrating these agents into prostate cancer practice. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are av...
2021-04-2615 minOncology On The Go
Oncology On The Go1-on-1 with David Johnson: Enveric's Endocannabinoid Products for GlioblastomaIn this episode, CancerNetwork sat down for a conversation with David Johnson, chairman and CEO of Enveric Biosciences. Johnson gave a thorough background of the biosciences company, and detailed the endocannabinoid products Enveric is developing to positively impact the quality of life for patients with glioblastoma. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast anywhere podcasts are available.
2021-04-1216 minOncology On The Go
Oncology On The GoImpact of Treatment Refusal on Survival for Small Cell Lung CancerIn this episode, CancerNetwork examines an article from the March issue of the Journal ONCOLOGY titled “Factors Associated With Treatment Refusal and Impact of Treatment Refusal on Survival of Patients With Small Cell Lung Cancer.” The original research article found that treatment refusal among patients with small cell lung cancer was associated with worse survival, and strategies to increase patient acceptance of the recommended treatment need to be studied further. CancerNetwork spoke with one of the authors, KM Monirul Islam, MD, of the Georgia Medical Center, to learn more about this research. For the response perspective, CancerNetwork spoke with Jenn...
2021-03-1524 minOncology On The Go
Oncology On The Go1-on-1 with Richard Schilsky, MD: Molecular Profiling in GI CancersThis week, CancerNetwork sat down for a 1-on-1 conversation with former Chief Medical Officer and Executive Vice President of ASCO, Richard Schilsky, MD, to discuss ASCO’s 2021 "Advance of the Year," molecular profiling driving progress in gastrointestinal cancers.  Schilsky discussed the progress being made in this field and the top research contributing to the momentum in gastrointestinal cancers, while also elaborating on health equity in cancer research, ASCO’s top research priorities moving forward, and more. He also explained the changes forced on clinical trials due to the coronavirus disease 2019 (COVID-19) pandemic, and how he anticipates trial...
2021-03-0117 minOncology On The Go
Oncology On The GoUtility of 21-Gene Recurrence Score for Node-Positive Breast CancerThis week, CancerNetwork examined a review article published in the February issue of the Journal ONCOLOGY titled “Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer.”   The piece highlights the existing literature regarding the prognostic and predictive capabilities of the 21-gene recurrence score in patients with node-positive breast cancer, focusing on current practice patterns and emerging applications from the surrounding literature.   For the summary, CancerNetwork spoke with 2 authors of the review, Alison Laws, MD, an associate surgeon at the Brigham and Women’s Hospital and Philip Poorvu, MD, a medical oncologist at the Dana Farber Cancer Institute. Laws and Poorvu p...
2021-02-1531 minOncology On The Go
Oncology On The GoMediterranean Diet's Association with Localized Prostate CancerThis week, CancerNetwork spoke with Justin Gregg, MD, about a study published in Cancer titled “Adherence to the Mediterranean diet and grade group progression in localized prostate cancer: An active surveillance cohort.”   Gregg, an assistant professor of urology at The University of Texas MD Anderson Cancer Center and the lead author of the study, explained that the Mediterranean diet was associated with a lower risk of Gleason Grade group progression among men with localized prostate cancer on active surveillance. Larger follow-up studies are still necessary to verify the patient- and cancer-specific effects of adherence to the Mediterranean diet. Don’t...
2021-02-0110 minOncology On The Go
Oncology On The GoGuidelines for Palliative Treatment of Spinal MetastasesIn this episode, CancerNetwork speaks with Ashwatha Narayana, MD, a professor and chairman of radiation oncology at Northern West Chester Hospital. Narayana co-authored a review article titled “Guidelines for Palliative Treatment of Spinal Metastases: Choosing Between Stereotactic Body Radiation Therapy and Conventional Fractionation.”    The article published in the January issue of the Journal ONCOLOGY and discusses the surrounding literature regarding palliative radiation therapy for spinal metastases. More, the team provides recommendations algorithmically to best select patients with metastatic disease for palliative spinal SBRT.
2021-01-1814 minOncology On The Go
Oncology On The Go1-on-1 with Che-Kai Tsao, MD: Smoking Cessation and Patient ScreeningIn the first episode of 2021, CancerNetwork spoke with Che-Kai Tsao, MD, a medical oncologist at Mount Sinai. Tsao discussed smoking cessation, its relation to cancer, and screenings for patients. More, he went into detail regarding the National Cancer Institute-funded smoking cessation program, a program Mount Sinai has been a part of for a number of years.  Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
2021-01-0410 minOncology On The Go
Oncology On The GoRecommending Patient-Reported Outcomes of Pain for Cancer CareIn this episode of "Oncology Peer Review On-The-Go", CancerNetwork takes a look at an article publishing in early 2021 for the Journal ONCOLOGY, titled “Patient-Reported Outcomes of Pain and Related Symptoms in Integrative Oncology Practice and Clinical Research: Evidence and Recommendations.” The piece summarizes current and validated patient-reported outcomes (PROs) specific to cancer-related pain. The piece also recommends commonly used PROs to be standardized to aid integrative oncology clinicians and researchers in both patient care and study design. For the first of 2 interviews regarding this piece, CancerNetwork spoke with 3 authors of the article, W. Iris Zhi, MD, PhD, and Ting...
2020-12-2140 minOncology On The Go
Oncology On The Go1-on-1 with Zuri Murrell, MD: Colorectal Cancer in Black PatientsIn this edition of "Oncology Peer Review On-The-Go," CancerNetwork spoke with Zuri Murrell, MD, for a conversation regarding the rising rates of colorectal cancer for younger individuals, as well as the significantly higher incidence and death rates for black patients of this cancer type.    Murrell, a colorectal surgeon and cancer specialist at Cedars-Sinai, explained that obesity, diabetes, smoking, and a family history of colorectal cancer may all play a role in the increasing rate. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available .
2020-12-0733 minOncology On The Go
Oncology On The GoFertility Preservation Decision-Making for Adolescents with CancerThis latest episode of "Oncology Peer Review On-The-Go" looks at an article published in the November issue of the journal ONCOLOGY, titled “Supporting Decision-Making on Fertility Preservation Among Adolescent and Young Adult Women With Cancer.” The piece examines oncofertility, unexpected cancer diagnoses and the decision-making process for young adult patients. For a breakdown of the article, CancerNetwork spoke with co-author of the review article, Jackelyn Payne, MPH, MA, a doctoral student in the department of psychology at Stony Brook University. For the response perspective, CancerNetwork spoke with Elizabeth Constance, MD, who is an associate professor at the University of N...
2020-11-2332 minOncology On The Go
Oncology On The GoBarriers to Pancreatic Cancer Clinical Trial EnrollmentThis episode of "Oncology Peer Review On-The-Go" examines an article published in the October issue of the journal ONCOLOGY, titled “Barriers to Clinical Trial Enrollment in Patients With Pancreatic Adenocarcinoma Who Are Eligible for Early-Phase Clinical Trials.” The piece was written by Rachael Galvin, DO, MPH, Christine Chung, DO, Ella Achenbach, Oliwier Dziadkowiec, PhD, and Shiraj Sen, MD, PhD, and focuses on what keeps patients of this aggressive form of pancreatic cancer from pursuing enrollment in clinical trials. For a summary of the article, CancerNetwork spoke with lead author of the study, Rachael Galvin, DO, MPH, from the Swedish Medical Cent...
2020-11-0929 minOncology On The Go
Oncology On The GoCancer Care Management During the COVID-19 PandemicThis episode of “Oncology Peer Review On-The-Go” examines an article published in the October issue of the journal ONCOLOGY, titled “Considerations for the Management of Oncology Patients During the COVID-19 Pandemic.” The piece focuses on the management of the coronavirus pandemic and best practices to effectively manage patients with cancer. For detailed information regarding the article, CancerNetwork spoke with two authors of the study, Jeffrey Schneider, MD, and Marc Braunstein, MD, PhD, from the NYU Winthrop Hospital.   Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
2020-10-2632 minOncology On The Go
Oncology On The GoThe Psychological Aspect of Patients in Phase 1 Clinical TrialsThis episode of "Oncology Peer Review On-The-Go" features an article published in the September issue of the journal ONCOLOGY. The article is titled “Screening for Phase 1 Clinical Trials: An Opportunity to Evaluate Psychological States and Re-educate Patients on Prognosis?” It was written by Sarah Moreland, MD, and Shiraj Sen, MD, PhD, and focuses on physician-patient communication and the psychosocial impact of cancer diagnoses on patients. For more information regarding the article, CancerNetwork spoke with Dr. Moreland from the Medical Center of Aurora. For the article’s response perspective, CancerNetwork spoke with Daniel McFarland, DO, of the Memorial Sloan Ketter...
2020-10-1236 minOncology On The Go
Oncology On The GoMolecular Profiling in Metastatic Colorectal CancerThis episode of "Oncology Peer Review On-The-Go" examines a review article published in the September issue of the journal ONCOLOGY. The article, “Molecular Profiling in Metastatic Colorectal Cancer,” was written by Samantha Armstrong, MD, Rita Malley, MS, and Benjamin Weinberg, MD. The piece discusses the epidemiology, tumor location, and mutational landscape of metastatic colorectal cancer. For an in-depth evaluation of that piece, CancerNetwork spoke with Armstrong and Weinberg from the Georgetown Lombardi Comprehensive Cancer Center.   For the article’s response perspective, CancerNetwork spoke with John Marshall, MD, of the Georgetown Lombardi Comprehensive Cancer Center. Dr. Marshall discussed the cost, quality...
2020-09-2824 minOncology On The Go
Oncology On The Go1-on-1 with Dr. Michael Randell: New ACS Guidelines for Cervical Cancer CancerNetwork speaks with Michael Randell, MD, FACOG, of OBGYN Atlanta to learn more about the new cervical cancer screening guidelines released by the American Cancer Society. In the interview, Randell expresses his concerns with the updated guidelines, and details what he recommends to patients. Don’t forget to subscribe to the Oncology Peer Review On-The-Go podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
2020-09-1408 minOncology On The Go
Oncology On The GoIs Next-Generation Sequencing a Right for Patients with GI Cancers?In the latest episode of "Oncology Peer Review On-The-Go," CancerNetwork examines a Q&A piece in the August issue of the journal ONCOLOGY discussing next-generation sequencing for gastrointestinal cancers. The article is titled “Ushering in the Era of Precision Medicine” and it focuses on a conversation with Tanios Bekaii-Saab, MD, of the Mayo Clinic in Phoenix, Arizona.    For a responding perspective, CancerNetwork spoke with Howard Hochster, MD, of the Rutgers Cancer Institute of New Jersey. Dr. Hochster discussed his feelings regarding next-generation sequencing, and suggests alternative ways to treat patients with GI cancers.   Don’t forget to subscribe to the "Oncology...
2020-08-3132 minOncology On The Go
Oncology On The GoThe COVID-19 Pandemic's Impact on Cancer ScreeningsIn this week’s episode, CancerNetwork speaks with Christopher McNair, PhD, of the Sidney Kimmel Cancer Center – Jefferson Health for an in-depth discussion on how the COVID-19 pandemic has impacted cancer screenings. Then, CancerNetwork speaks with Lisa Berry Edwards, managing director of external affairs for the PreventCancer Foundation, to talk about their “Back on the Books” initiative working to get cancer screenings and regular appointments rescheduled during the pandemic. Don’t forget to subscribe to the Oncology Peer Review On-The-Go podcast on Apple Podcasts, Spotify or anywhere podcasts are available, or listen online at www.cancernetwork.com.
2020-08-1720 minOncology On The Go
Oncology On The GoClinical Trials System and the COVID-19 PandemicOn this week's episode of Oncology Peer Review On-The-Go, CancerNetwork examines an article from the July issue of the journal ONCOLOGY entitled “Oncology Clinical Trials During the COVID-19 Pandemic.” The article was written by Aline Lara, MD, Denis Jardim, MD, PhD, and Diogo Bastos, MD. CancerNetwork spoke with Dr. Lara and Dr. Bastos for an overview of the review article. Then, CancerNetwork speaks with Mehmet Copur, MD, of the Morrison Cancer Center for a peer reviewed perspective. Dr. Copur discussed how to navigate clinical trials during the pandemic and the need to improve the clinical trial system in the...
2020-08-0326 minOncology On The Go
Oncology On The Go1-on-1 with Dr. Xu Ji: Mental Health Among Cancer SurvivorsIn this episode of Oncology Peer Review On-The-Go, CancerNetwork speaks 1-on-1 with Xu Ji, PhD, MSPH, of the Winship Cancer Institute regarding her research entitled "Mental Health Among Nonelderly Adult Cancer Survivors: A National Estimate."
2020-07-2014 minOncology On The Go
Oncology On The GoMinority Treatment Disparities and Clinical Trial Enrollment CancerNetwork talks with Christopher Flowers, MD, of the MD Anderson Cancer Center regarding "Strategies for Overcoming Disparities for Patients With Hematologic Malignancies and for Improving Enrollment on Clinical Trials" from the journal ONCOLOGY. Then, Julie Vose, MD, of the University of Nebraska Medical Center gives her perspective on the factors leading to cancer care disparities and the significance of representative enrollment in clinical trials.
2020-07-0617 min